Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

Table 1 Baseline patient characteristics

Characteristic	Value
Age, median (range), y	63 (37–71)
Sex, female	9 (56)
BMI, median (range), kg/m²	27.7 (16.4–43.3)
Histology
DLBCL	15 (94)
FL	1 (6)
Treatment history
Number of prior lines, median (range)	4 (2–6)
Autologous transplant, yes	8 (50)
Bridging therapy
Yes	14 (88)
Chemotherapy	11 (69)
Radiotherapy	3 (19)
Number of CAR T-cell infusions
1	6 (38)
2	10 (63)
Number of imaging sessions
2	7 (44)
3	8 (50)
> 3	1 (6)
Lugano classification at t₁
CMR	2 (13)
PMR	5 (31)
NMR	2 (13)
PMD	7 (44)
Clinical follow-up
Follow-up survivors, median (range), mo	42.6 (36.0–48.2)
PFS from 1st infusion, median (IQR), mo	3.9 (1.8–7.8)
OS from 1st infusion, median (IQR), mo	9.3 (4.7–18.3)
PFS from t₁, median (IQR), mo	3.2 (1.1–6.1)
OS from t₁, median (IQR), mo	8.6 (4.0–17.6)

Baseline patient characteristics at the time of CAR T-cell infusion, infusion and imaging details and clinical outcomes of therapy. Values are presented as n (%) unless otherwise stated. CMR Complete Metabolic Response, PMR Partial Metabolic Response, NMR No Metabolic Response, PMD Progressive Metabolic Disease

ISSN: 1470-7330